IFRX•benzinga•
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
Summary
InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cash runway.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 28, 2025 by benzinga